Karyopharm Highlights Phase 3 SENTRY Trial Progress in Myelofibrosis
NEWTON, Mass., June 1, 2026 Karyopharm Therapeutics has announced that it will host an investor conference call featuring leading...
myelofibrosis
Advertisement
Incyte Corporation Wins FDA Approval for Jakafi XR
WILMINGTON, Del., May 1, 2026 Incyte Corporation has secured U.S. Food and Drug Administration (FDA) approval for Jakafi XR™...
Eli Lilly to Acquire Ajax Therapeutics in $2.3B Oncology Deal
INDIANAPOLIS, NEW YORK & CAMBRIDGE, Mass., April 27, 2026 Eli Lilly and Company has announced a definitive agreement to...
Karyopharm SENTRY Trial Advances Myelofibrosis Treatment
Newton, Massachusetts, USA, April 21, 2026 In a major development in hematologic oncology, Karyopharm Therapeutics Inc. has announced that...
Editas Medicine Advances Gene-Editing Therapy EDIT-401
Cambridge, Massachusetts – September 2, 2025 Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene-editing biotechnology company, has nominated EDIT-401,...
Advertisements
Sumitomo Pharma Unveils Promising Data in Blood Cancers
Marlborough, Massachusetts – November 3, 2025 Sumitomo Pharma America, Inc. (SMPA) announced compelling new investigational data from multiple clinical...
Advertisement
